vs
Side-by-side financial comparison of CLOVER HEALTH INVESTMENTS, CORP. (CLOV) and Bio-Techne (TECH). Click either name above to swap in a different company.
CLOVER HEALTH INVESTMENTS, CORP. is the larger business by last-quarter revenue ($487.7M vs $295.9M, roughly 1.6× Bio-Techne). Bio-Techne runs the higher net margin — 12.8% vs -10.1%, a 23.0% gap on every dollar of revenue. On growth, CLOVER HEALTH INVESTMENTS, CORP. posted the faster year-over-year revenue change (44.7% vs -6.4%). Over the past eight quarters, CLOVER HEALTH INVESTMENTS, CORP.'s revenue compounded faster (18.6% CAGR vs 4.2%).
Clover Health Investments, Corp. is an American health care company founded in 2014. The company provides Medicare Advantage (MA) insurance plans and operates as a direct contracting entity with the U.S. government. The company manages care for Medicare beneficiaries in 11 states and started trading publicly on January 8, 2021.
Bio-Techne Corporation is an American life sciences company that develops, manufactures and sells life science reagents, instruments and services for the research, diagnostic, and bioprocessing markets.
CLOV vs TECH — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2026
| Metric | | |
|---|---|---|
| Revenue | $487.7M | $295.9M |
| Net Profit | $-49.3M | $38.0M |
| Gross Margin | — | 64.6% |
| Operating Margin | -10.1% | 18.4% |
| Net Margin | -10.1% | 12.8% |
| Revenue YoY | 44.7% | -6.4% |
| Net Profit YoY | -123.2% | 68.3% |
| EPS (diluted) | — | $0.24 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $487.7M | $295.9M | ||
| Q3 25 | $496.6M | — | ||
| Q2 25 | $477.6M | $317.0M | ||
| Q1 25 | $462.3M | $316.2M | ||
| Q4 24 | $337.0M | $297.0M | ||
| Q3 24 | $331.0M | $289.5M | ||
| Q2 24 | $356.3M | $306.1M | ||
| Q1 24 | $346.9M | $303.4M |
| Q4 25 | $-49.3M | $38.0M | ||
| Q3 25 | $-24.4M | — | ||
| Q2 25 | $-10.6M | $-17.7M | ||
| Q1 25 | $-1.3M | $22.6M | ||
| Q4 24 | $-22.1M | $34.9M | ||
| Q3 24 | $-9.2M | $33.6M | ||
| Q2 24 | $7.4M | $40.6M | ||
| Q1 24 | $-19.2M | $49.1M |
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | 24.5% | 63.2% | ||
| Q2 24 | 30.3% | 66.4% | ||
| Q1 24 | 23.6% | 67.4% |
| Q4 25 | -10.1% | 18.4% | ||
| Q3 25 | -4.9% | — | ||
| Q2 25 | -2.2% | -7.5% | ||
| Q1 25 | -0.3% | 12.2% | ||
| Q4 24 | -6.4% | 16.0% | ||
| Q3 24 | -2.7% | 13.8% | ||
| Q2 24 | 2.0% | 15.0% | ||
| Q1 24 | -6.5% | 22.1% |
| Q4 25 | -10.1% | 12.8% | ||
| Q3 25 | -4.9% | — | ||
| Q2 25 | -2.2% | -5.6% | ||
| Q1 25 | -0.3% | 7.1% | ||
| Q4 24 | -6.6% | 11.7% | ||
| Q3 24 | -2.8% | 11.6% | ||
| Q2 24 | 2.1% | 13.3% | ||
| Q1 24 | -5.5% | 16.2% |
| Q4 25 | — | $0.24 | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.11 | ||
| Q1 25 | — | $0.14 | ||
| Q4 24 | — | $0.22 | ||
| Q3 24 | — | $0.21 | ||
| Q2 24 | — | $0.26 | ||
| Q1 24 | — | $0.31 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $78.3M | $172.9M |
| Total DebtLower is stronger | — | $260.0M |
| Stockholders' EquityBook value | $308.7M | $2.0B |
| Total Assets | $541.0M | $2.5B |
| Debt / EquityLower = less leverage | — | 0.13× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $78.3M | $172.9M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $162.2M | ||
| Q1 25 | — | $140.7M | ||
| Q4 24 | $194.5M | $177.5M | ||
| Q3 24 | $288.0M | $187.5M | ||
| Q2 24 | $254.8M | $152.9M | ||
| Q1 24 | $208.3M | $145.3M |
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
| Q4 25 | $308.7M | $2.0B | ||
| Q3 25 | $340.9M | — | ||
| Q2 25 | $344.2M | $1.9B | ||
| Q1 25 | $336.1M | $2.0B | ||
| Q4 24 | $341.1M | $2.1B | ||
| Q3 24 | $342.2M | $2.1B | ||
| Q2 24 | $324.9M | $2.1B | ||
| Q1 24 | $292.5M | $2.0B |
| Q4 25 | $541.0M | $2.5B | ||
| Q3 25 | $559.7M | — | ||
| Q2 25 | $575.0M | $2.6B | ||
| Q1 25 | $583.7M | $2.6B | ||
| Q4 24 | $580.7M | $2.7B | ||
| Q3 24 | $653.0M | $2.7B | ||
| Q2 24 | $674.2M | $2.7B | ||
| Q1 24 | $671.8M | $2.7B |
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-66.9M | — |
| Free Cash FlowOCF − Capex | $-69.0M | — |
| FCF MarginFCF / Revenue | -14.1% | — |
| Capex IntensityCapex / Revenue | 0.4% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-69.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-66.9M | — | ||
| Q3 25 | $12.1M | — | ||
| Q2 25 | $5.4M | $98.2M | ||
| Q1 25 | $-16.3M | $41.1M | ||
| Q4 24 | $34.8M | $84.3M | ||
| Q3 24 | $50.0M | $63.9M | ||
| Q2 24 | $44.8M | $75.5M | ||
| Q1 24 | $25.9M | $81.0M |
| Q4 25 | $-69.0M | — | ||
| Q3 25 | $11.4M | — | ||
| Q2 25 | $4.8M | $93.3M | ||
| Q1 25 | $-16.5M | $31.0M | ||
| Q4 24 | $33.3M | $77.5M | ||
| Q3 24 | $49.6M | $54.7M | ||
| Q2 24 | $44.4M | $57.5M | ||
| Q1 24 | $25.5M | $64.5M |
| Q4 25 | -14.1% | — | ||
| Q3 25 | 2.3% | — | ||
| Q2 25 | 1.0% | 29.4% | ||
| Q1 25 | -3.6% | 9.8% | ||
| Q4 24 | 9.9% | 26.1% | ||
| Q3 24 | 15.0% | 18.9% | ||
| Q2 24 | 12.5% | 18.8% | ||
| Q1 24 | 7.3% | 21.3% |
| Q4 25 | 0.4% | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | 0.1% | 1.5% | ||
| Q1 25 | 0.0% | 3.2% | ||
| Q4 24 | 0.5% | 2.3% | ||
| Q3 24 | 0.1% | 3.2% | ||
| Q2 24 | 0.1% | 5.9% | ||
| Q1 24 | 0.1% | 5.4% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | 6.04× | 1.86× | ||
| Q1 24 | — | 1.65× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CLOV
Segment breakdown not available.
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
